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Essential hypertension, defined as elevated levels of blood pressure (BP) without any obvious cause, is a major risk factor
for coronary heart disease, stroke, and renal disease. BP levels and susceptibility to development of essential hypertension
are partially determined by genetic factors that are poorly understood. Similar to other efforts to understand complex,
non-Mendelian phenotypes, genetic dissection of hypertension-related traits employs genomewide linkage analyses of
families and association studies of patient cohorts, to uncover rare and common disease alleles, respectively. Family-
based mapping studies of elevated BP cover the large intermediate ground for identification of genes with common
variants of significant effect. Our genomewide linkage and candidate-gene–based association studies demonstrate that a
replicated linkage peak for BP regulation on human chromosome 1q, homologous to mouse and rat quantitative trait
loci for BP, contains at least three genes associated with BP levels in multiple samples: ATP1B1, RGS5, and SELE. Individual
variants in these three genes account for 2–5-mm Hg differences in mean systolic BP levels, and the cumulative effect
reaches 8–10 mm Hg. Because the associated alleles in these genes are relatively common (frequency 15%), these three
genes are important contributors to elevated BP in the population at large.
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Essential hypertension (EH [MIM 145500]), defined as
chronically elevated blood pressure (BP) occurring in the
absence of other predisposing conditions, affects 125% of
adults worldwide and is a significant risk factor for coro-
nary heart disease, stroke, and renal disease.1 Genes play
a major role in determination of BP and EH susceptibility,
because the heritability of BP levels has been estimated
to be 30%–35%.2 Rare syndromic forms of hyper- and
hypotension show Mendelian inheritance, and the mu-
tations underlying some of these disorders have been iden-
tified by positional cloning and candidate-gene analyses.3,4
These genes all regulate renal salt reabsorption, in accor-
dance with earlier work by Guyton5 and others that es-
tablished that the kidney plays a central role in BP regu-
lation. Mutations underlying monogenic hypertension are
rare in the general population; thus, the genetic basis of
EH remains poorly understood, and numerous loci seg-
regating alleles of smaller effect are still unidentified.
More than 30 genomewide linkage studies of EH and
BP-related phenotypes have been published (reviewed by
Garcia et al.6 and Samani7), by use of a variety of study
designs and populations. Meta-analyses of these studies
indicate that there is no single genomic region with a large
effect on BP or EH. However, many linkage studies were
insufficiently powered to detect small effects. Neverthe-
less, several genomic regions, such as 1q, 2p, 3p, 6q, 7q,
12q, 15q, 17q, 18q, and 19p, were validated by multiple
studies and are likely to contain EH-susceptibility loci.7
These linkage regions, typical of complex traits, contain
hundreds of genes. Therefore, it is difficult to decide which
linkage regions warrant costly gene identification.
We report the characterization of a linkage region on
chromosome 1q23-q32 that is validated in several BP and
EH linkage studies and is supported by BP-related QTL
mapping studies in the rat and mouse. To optimize power,
we started with samples collected through family-based
studies enriched with subjects with elevated BP unaltered
by medication. We also vigorously rid our pedigree struc-
ture, phenotype, and genotype, and marker data of all
detectable errors. Although the genetic basis of hyperten-
sion is largely unknown, physiological processes that reg-
ulate and alter BP are better understood. Therefore, we
took advantage of the published literature and annotation
of known genes in our linkage region, and we focused on
genes that are in pathways that determine BP levels or
have a regulatory function. We found evidence of asso-
ciation between three genes and BP in multiple samples.
The genes are independently associated with BP levels,
and the cumulative effects of having multiple suscepti-
bility alleles at these three genes are estimated to be 8–10
mm Hg. Our results indicate that the 1q locus harbors
multiple EH-susceptibility genes that affect BP levels.
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Table 1. Samples Studied
Characteristic
Original Sample
Replication Sample
GenNet GENOA HyperGEN
EA AA EA AA EA AA
No. of subjects 1,010 816 1,324 1,620 810 325
No. of families 303 289 473 559 272 78
Mean age (years) 45.6  14.8 41.3  11.7 55.4  11.1 57.4  10.3 53.5  13.3 42.0  13.3
Male (%) 45 40 46 32 45 35
Mean SBP (mm Hg) 123.2  17.6 123.9  19.7 134.0  19.9 130.7  23.3 116.9  20.5 123.2  22.8
Mean DBP (mm Hg) 77.0  10.0 76.0  13.4 76.2  10.3 70.5  11.5 66.8  10.1 70.9  12.3
Mean BMI 29.0  6.1 30.4  8.4 30.4  6.3 30.9  6.6 28.4  5.9 30.9  7.4
Normotensive (%) 68 66 33 29 61 62
EH (%)a:
Medicated 22 22 65 61 37 32
Unmedicated 10 12 2 10 2 6
a Medicated p hypertensive patients taking hypertension medication; Unmedicated p hypertensive individuals not taking hypertension
medication.
Material and Methods
Study Population
Samples used in this study were collected through three networks
of the NHLBI Family Blood Pressure Program (FBPP): GenNet,
GENOA, and HyperGEN. Details of the FBPP subjects have been
published elsewhere,8 and characteristics of GenNet, GENOA, and
HyperGEN samples are provided in table 1. GenNet samples were
used in the original linkage and association studies and consist
of 1,826 individuals from 592 families that are either European
American (EA) or African American (AA), collected from 1995 to
2000. Probands were subjects between the ages of 18 and 50 years
with BP in the upper 25% of the age- and sex-specific BP distri-
bution. Overall, 33% of the study subjects were clinically hyper-
tensive, with systolic BP (SBP) 140 or diastolic BP (DBP) 90
mm Hg, or were taking hypertension medication at the time of
the study. The 592 families consist of bigenerational pedigrees
and sibships. Most (91%) of the GenNet AA families consisted of
siblings only, whereas 24%, 29%, and 47% of GenNet EA families
included genotype and phenotype information from both, one,
and no parents, respectively. Two other FBPP networks, GENOA
and HyperGEN, provided EA and AA samples, to confirm the
association between chromosome 1 variants and BP (2,944 and
1,135 samples from GENOA and HyperGEN, respectively). Pro-
bands were those with either severe or familial hypertension. On
the basis of the same definition as above, 69% and 39% of the
GENOA and HyperGEN subjects, respectively, are clinically hy-
pertensive. This study was approved by the institutional review
boards at the parent institutions of all participating FBPP
laboratories.
Phenotype
BP measurement and the inclusion and exclusion criteria for Gen-
Net, GENOA, and HyperGEN samples have been described else-
where.8–11 For example, two manual BP readings were taken from
GenNet subjects with the use of a standard mercury manometer.
The average SBP and DBP readings were used for analysis. Pulse
pressure (PP) was defined as SBP minus DBP. BMI was calculated
as weight in kilograms divided by height in meters squared. To
avoid likely erroneous extreme BP values, all SBP reading 1180
mm Hg or !85 mm Hg and all DBP readings 1110 mm Hg or !40
mm Hg were used in the analysis only if the difference between
the first and second readings was !10 mm Hg. For some analyses,
BP values for the subjects taking hypertension medication were
adjusted for an average treatment effect by addition of 10 mm
Hg to SBP and 5 mm Hg to DBP, as suggested elsewhere.12
Genotyping and Data Quality Control
Microsatellite markers used in genomewide linkage scans were
genotyped by the Mammalian Genotyping Service from 1998 to
2000, by use of five sets of markers. The average intermarker
distance was 9.2 cM. Data from the 22 autosomes were analyzed
and presented. To further characterize the 1q linkage region, 16
additional microsatellite markers in 1q23.1-32.1 were genotyped
using the deCODE genotyping service. After fine mapping, the
average intermarker distance in the 1q region was reduced from
8.2 Mb to !1.9 Mb.
The microsatellite genotypes and family data of GenNet un-
derwent an extensive data-cleaning process that involved (1)
identification and deletion of markers in which alleles were called
inconsistently among the seven batches of genotypes generated,
(2) validation and correction of family structures on the basis of
the mean and SD of allele sharing (by use of microsatellite ge-
notype data) of all pairs of individuals within the study, and (3)
removal of all other probable genotyping errors that are incon-
sistent with Mendelian transmission. Overall, 10% of the geno-
types were unavailable because of genotyping failure or deletion
of erroneous data. Our data-cleaning protocol, developed on the
basis of our experience with marker and family data for 12,041
FBPP subjects, and examples of the importance data quality
can have for the outcome of genetic analyses are published
elsewhere.13
SNP genotyping of 1q candidate genes was done using 5′-
nuclease–based assay (TaqMan [ABI]). Data quality of SNP ge-
notypes was established by three methods: reproducibility of con-
trol DNA samples, expected Mendelian inheritance of alleles
within a family (PedCheck14), and Hardy-Weinberg equilibrium
tests ( ). For the last, we used all unrelated individuals inP 1 .05
our study, analyzing samples from different ethnic groups sepa-
rately, using the analysis package Haploview.15
Candidate-Gene Selection
Given our incomplete understanding of BP regulation, a system-
atic search for variants associated with BP should be conducted
for all genes in the linkage region, and this effort is underway.
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Figure 1. Genetic evidence for chromosome 1 linkage to DBP in
GenNet EA samples. MLOD scores from an original linkage scan
that analyzed all samples, regardless of medication status (10 cM,
all), excluding those from patients taking hypertension medication
(unmed), and with additional markers in the linked region (after
fine mapping). The locations of the nine candidate genes are in-
dicated (colored squares).
Table 2. Hypertension Candidate Genes
in 1q Linkage Region
The table is available in its entirety in the online
edition of The American Journal of Human Genetics.
During the initial round of candidate-gene selection, 35 genes
were chosen on the basis of their known or putative functions,
and they are listed in table 2. These protein products play roles
in salt transport, signal transduction, inflammatory response, re-
nal filtration, lipid metabolism, and vascular function—pathways
thought to be dysregulated in hypertension. They also included
regulators and signal transduction proteins with little or no
known function related to BP regulation. From this list, nine
genes were selected for SNP analysis (fig. 1). Eight genes were
selected on the basis of their physical proximity to the markers
with the maximum LOD (MLOD) score in the original linkage
scan and the two new peaks after fine mapping: RGS4 (MIM
602515), RGS5 (MIM 603276), ATP1B1 (MIM 182330), SELL (MIM
153240), SELE (MIM 131210), SELP (MIM 173610), REN (MIM
179820), and ADORA1 (MIM 102775). The distances between
these genes and the linkage markers with MLOD scores ranged
between 27 and 642 kb. In addition, we also took advantage of
the mapping of BP-related loci in mice. By the combining of the
linkage signals from two different crosses of hypertensive and
normotensive strains (C57BL/6J # A/J and SWR/J # C3H/HeJ),
the 95% CI of the mouse BP-related QTL on chromosome 1 was
refined to an 18-cM region,16 a region smaller than the homol-
ogous BP-related linkage region identified in the human and rat.
Mouse homologs of six genes selected using our first criterion,
ATP1B1, SELE, SELP, SELL, ADORA1, and REN, are located in this
18-cM region. The exceptions, RGS4 and RGS5, are the candidate
genes closest to the MLOD score peak of 4.3 (175.6 cM). High-
density haplotype mapping of the same four mouse strains iden-
tified two regions (1.8 Mb and 2.5 Mb in size) that are shared by
the hypertensive strains and are not shared by the normotensive
strains.16 Another gene from our list of 35 positional candidate
genes, NPHS2 (MIM 604766), is located in one of these two
regions and was also selected.
SNP Selection
The 58 SNPs genotyped and analyzed were those validated by
dbSNP or by our own sequencing of ATP1B1, SELE, and RGS5. All
genotyped SNPs have minor-allele frequencies 10.05 in GenNet
samples. The average distance between SNPs within a gene is 5.7
kb. To uncover novel variants associated with BP regulation in
RGS5, SELE, and ATP1B1, we sequenced 100 unrelated GenNet
EA samples by use of BigDye terminator system (ABI) with PCR
and sequencing oligonucleotide primers designed using Primer3.
For each of the three genes, all exons (and flanking intronic se-
quences) and conserved noncoding regions in the associated
regions (FBAT ) were sequenced.P ! .05
Genetic Analysis
Genomewide linkage scan.—We applied nonparametric linkage
analysis, using the variance-components approach implemented
by analysis packages GENEHUNTER (version 2.1) and SOLAR (ver-
sion 2.1). SBP, DBP, and PP were adjusted for age and sex, whereas
other factors, such as BMI, smoking status, and diabetes, did not
alter linkage signals significantly and were not included as co-
variates in the results presented. EA and AA samples were ana-
lyzed separately and in combination. Individuals taking anti-
hypertensive medications at the time of the study either were
analyzed with the use of the treated BP values or were excluded
from analysis. Because the location and the magnitude of MLOD
scores obtained by use of GENEHUNTER versus SOLAR were
nearly identical (the MLOD score obtained for chromosome 1
was 4.9 at 176 cM vs. 4.6 at 175 cM, respectively), only results
obtained from GENEHUNTER are presented in table 3 and fig-
ure 1.
Comparison of human, rat, and mouse linkage results.—When com-
paring our linkage scan results with the published literature, we
used rather stringent criteria to decide what constitutes a repli-
cated linkage signal. Only linkage regions with MLOD score 2
from each study were compared. Furthermore, the linkage result
was considered replicated only when the markers closest to the
MLODs of the two studies are identical. If different marker panels
were used, replication was accepted only if the physical locations
(based on National Center for Biotechnology Information [NCBI]
build 34) of the markers closest to the MLODs in both studies
are within the same cytogenetic subband, such as 1q24.
For comparison of our linkage results with rat BP-related QTL
findings, we used the cytogenetic regions homologous to rat QTL
clusters described by Stoll et al.17 For mouse QTLs, when avail-
able,16,18,19 we used the human cytogenetic regions homologous
to rat and mouse QTLs stated in the literature. When the position
was not well mapped,20 we used the comparative genomic tools
offered by the UCSC Genome Browser and the Comparative Maps
Web site to locate the region in the human genome homologous
to the mouse QTL.
Candidate-gene SNP association test.—Pairwise linkage disequilib-
rium (LD) between candidate-gene SNPs was calculated using
Haploview,15 and the LD-block definition was obtained from ref-
erence.21 The software package FBAT22 was used for family-based
association tests for age- and sex-adjusted SBP and DBP. To test
for possible haplotype effects, we used windows of two and three
adjacent SNPs across the genes via haplotype FBAT (HBAT).23 As-
sociations with each of the 58 SNPs, as well as both global and
haplotype-specific associations, were evaluated under the addi-
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Table 3. Hypertension-Susceptibility Loci from Genomewide Linkage Mapping of GenNet Samples
Location
Position
(cM) Phenotype Samplesa MLOD Other Studiesb
Animal
Hypertension
Models
1q25 182 DBP EA 3.2 Family Heart Study30; Finnish Twin Cohort Study28;
Framingham Heart Study34
Rat17; mouse16,18
2q33 200 PP Combined 2.8 Amish Family Diabetes Study31 Mouse20,33
10p12 28 DBP EA 2.6 Stanford Asian Pacific Program in Hypertension and
Insulin Resistance27
…
10q21 86 DBP Combined 2.6 International Collaborative Study on Hypertension32 …
14q13 41 PP Combined 2.5 Finnish study26 …
14q32 106 PP Combined 3.0 … …
15q12 19 SBP Combined 2.4 … Mouse33
17q21 67 PP Combined 2.2 Framingham Heart Study29 Rat17; mouse33
a Combined p EA and AA samples combined.
b Other hypertension linkage studies that provide genetic evidence of BP-related loci in the same genomic regions.
tive genetic model. The null hypothesis of no association in the
presence of linkage was tested using the -e flag, which provides
an empirical variance for the test statistic, and the -p flag, which
provides Monte Carlo P values for the test statistics (up to 100,000
permutations). Since similar results were obtained, providing evi-
dence of association with the same SNPs and haplotypes, only
Monte Carlo P values calculated before correction for multiple
testing are presented.
Effect-size estimation.—Population-based estimates of the effect
of each SNP on age- and sex-adjusted SBP were made using general
estimating equations (GEE) to account for familial correlation,
as described elsewhere.24 This method, available in the analy-
sis package PBAT25 (option 2), uses all available families (includ-
ing uninformative families that do not contribute to the FBAT
statistics) and is robust against population admixture and
stratification.
Corrections for multiple testing.—Because we analyzed multiple
SNPs that are in strong LD with each other and multiple phe-
notypes (such as SBP and DBP) that are also highly correlated,
the individual FBAT tests performed were not truly independent.
We attempted to correct for multiple testing without overly pe-
nalizing the tests. First, we determined the number of “indepen-
dent” SNPs by counting SNPs in strong LD or an LD block as one
(using the same criteria used by Gabriel et al.21) and SNPs outside
of LD blocks individually. FBAT P values are corrected by the
number of “independent” SNPs, analyzed using the Bonferroni
method. Of the 58 SNPs analyzed in the GenNet EA samples, 31
are independent, and FBAT P values !.0016 are reported as sig-
nificant after correction for multiple testing. In GenNet AA sam-
ples, there are 34 independent SNPs, and P values !.0011 are
considered significant after correction. In our replication samples
(GENOA and HyperGEN), only nine SNPs with prior association
signals were analyzed. Because of their LD relationships, these
nine SNPs constitute four independent tests, and replication as-
sociation signals with are considered significant afterP ! .0125
correction for multiple testing.
Analysis of multiple independent phenotypes can also con-
tribute to type I errors. However, the phenotypes analyzed in our
study—SBP, DBP, and SBP/DBP adjusted for age, sex, medication,
etc.—are highly correlated with one another. In our study, un-
adjusted SBP and DBP have R2 of ∼0.50, and no adjustment for
testing of multiple phenotypes was made.
Results
Genomewide Linkage Scan of BP-Related QTLs
To gain insight into the genetic basis of EH, we applied
variance-components linkage analysis to 1,010 European
American (EA) samples and 816 African American (AA)
samples (table 1) collected through GenNet, one of the
FBPP8 networks. BP levels, instead of hypertension status,
were used as a quantitative trait to increase the power to
detect linkage. On the basis of a genomewide linkage scan
with the use of microsatellite markers (average density∼10
cM), eight regions had MLOD scores 12: 1q25, 2q33,
10p12, 10p21, 14q13, 14q32, 15q12, and 17q21 (table 3).
In six regions, linkage evidence was detected in both EA
and AA samples, and the MLODs reported are from the
combined data. For 1q25 and 10p12, evidence of linkage
was found in EA samples only. We compared our results
with those of published genomewide linkage studies for
EH and BP-related traits, and we observed that six of the
eight linkage regions we identified were confirmed by
other studies.26–32 Additional support for some of these
regions was evident from rodent BP-related QTLs identi-
fied through crossing inbred hypertensive and normo-
tensive, or salt-sensitive and salt-resistant, rat and mouse
strains.16–18,20,33
The strongest signal (MLOD 3.2) in our study was the
mapping of DBP variation to 182 cM on chromosome 1q
in GenNet EA samples. Initial evidence of this linkage in
the GenNet study was based on 65% of the samples pres-
ently available.9 Linkage between BP-related phenotypes
and the same region on 1q has been reported by three
independent studies of the human.28,30,34 Multiple studies
of QTL mapping in mouse and rat all found evidence of
BP-related QTLs in the precise homologous region to hu-
man 1q.16–18 Literature review of human and animal BP
linkage studies revealed that heterogeneity in study design
explains why some but not all studies found the chro-
mosome 1q locus (details available on request).
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Table 4. Information on 58 Candidate-
Gene SNPs
The table is available in its entirety in the online
edition of The American Journal of Human Genetics.
Figure 2. Association study of 58 candidate-gene SNPs with DBP (A) and SBP (B), on the basis of unmedicated BP values. Only P
values !.05 are plotted as log10(P). P values derived from GenNet EA samples (pink circles) and AA samples (blue circles) are shown
separately. P values from haplotype-based analyses are denoted as circles connected by lines. SNPs in each of the nine genes—RGS4,
RGS5, ATP1B1, SELP, SELL, SELE, NPHS2, ADORA1, and REN—are demarcated on the X-axis. The horizontal bars indicate SNPs in LD blocks
estimated using 377 unrelated EA samples (pink and red) and 276 AA samples (blue).
Fine Mapping of Chromosome 1q Linkage Region
The conventional confidence interval (MLOD-1) of 1q
linkage spans 57 cM and 48 Mb in genetic and physical
distances, respectively. To refine this genetic interval, we
genotyped 16 additional microsatellite markers. The orig-
inal linkage peak resolved into two distinct peaks, the first
with an MLOD of 4.3 at 175.6 cM and the second with
an MLOD of 1.8 at 218.5 cM (for unmedicated individuals
only) (fig. 1).
Association Study of Nine Positional Candidate Genes
From the 430 RefSeq genes in the 48-Mb region, we fo-
cused on 9 genes, chosen either because they are located
in close proximity to one of the linkage peaks or because
they are located in the homologous minimal linkage re-
gion defined by mouse BP-related QTLs: RGS4, RGS5,
ATP1B1, SELP, SELL, SELE, NPHS2, ADORA2, and REN (fig.
1). Fifty-eight SNPs located in or near these nine candidate
genes were genotyped in all GenNet AA and EA individ-
uals, to test for association with BP-related phenotypes
(SNP-related information detailed in table 4). GenNet pro-
bands have high to high-normal BP values but are not
necessarily clinically hypertensive. Therefore, we used
family-based association tests that use quantitative traits
and family information, since these tests have more power
than do traditional tests of association. Representative re-
sults based on single SNPs and on haplotypes constructed
from multiple SNPs are shown in figure 2. When DBP, the
phenotype that yielded the most significant linkage result,
was analyzed, significant association was detected for one
gene, ATP1B1 (most significant FBAT , for SNP23–Pp .002
SNP24) (fig. 2A). Association was detected not only in the
linked EA samples but also in the AA samples, despite the
lack of linkage evidence. This is not surprising, given the
greater power of association tests, compared with that of
linkage tests, to uncover common variants; moreover,
GenNet AA samples included fewer parents and were thus
underpowered to detect linkage.
When SBP was tested as the phenotype, associations
with an ATP1B1 SNP became more significant (Pp
, for SNP26 in EA samples) (fig. 2B), despite the fact.0006
that there was less evidence of linkage to SBP (MLOD 1.3).
In addition, we found significant associations with SBP for
two other genes in the AA samples. In RGS5, SNP3–SNP11
are associated with SBP in AA samples (the most significant
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Figure 3. Variants in RGS5, ATP1B1, and SELE independently associated with BP. Vertical lines in the horizontal bar denote the physical
relationships of candidate genes tested. The black line at top right indicates 2 Mb. RGS5 and ATP1B1 are separated by ∼5.96 Mb, and
ATP1B1 and SELE by 616 kb. The pairwise LD, as measured by D′, was calculated using Haploview (on the basis of unrelated GenNet EA
samples), and D′ is shown as . Cells are blank where , bright red indicates high LD ( ; ), pink indicates′ ′ ′100# D D p 1 D p 1 LOD 2
weaker LD ( ; ), white indicates no LD ( ; ), and blue indicates noninformative results ( ; ). Similar′ ′ ′D ! 1 LOD 2 D ! 1 LOD ! 2 D p 1 LOD ! 2
lack of LD between these three genes is observed in GenNet AA samples and HapMap samples (data not shown).
, for SNP4), and SNP12–SNP15 are associated inPp .001
EA samples (most significant , for SNP14). Vari-Pp .009
ants in SELE also demonstrated significant association for
AA samples, more so when haplotypes of multiple SNPs
were analyzed (for SNP43, ; for haplotype ofPp .04
SNP41–SNP43, ). Lack of consistent linkage andPp .001
association signals in GenNet AA and EA samples suggests
some degree of heterogeneity between these two samples.
RGS5 spans across 60.8 kb, and the 13 SNPs genotyped
are in two LD blocks (figs. 2 and 3). SNP3–SNP10, in the
first LD block, are associated with BP in GenNet AA sam-
ples, whereas SNP11–SNP15, in the second LD block, show
significant association with BP in the EA samples (fig. 2).
In ATP1B1, SNP18 and SNP26 are both associated with BP,
yet there is little evidence of LD between these two SNPs
(fig. 3). Importantly, haplotype-based association of these
two SNPs with SBP was more significant than that of the
single SNPs (in EA samples, , .0006, and .0002,Pp .009
for SNP18, SNP26, and the haplotype, respectively). Al-
though the resolution is limited by the LD between SNPs,
on the basis of these patterns of association, it is likely
that there are multiple functional sites in ATP1B1 and
RGS5 that influence BP.
The 58 SNPs that we genotyped are from functionally
relevant hypertension candidate genes located in a rep-
licated linkage region. Nevertheless, to avoid type I errors
from multiple comparisons, we corrected the P values of
the association signals for these three genes, to account
for testing of multiple SNPs, many of which are in strong
LD with each other. After correction, the strongest asso-
ciation signals (smallest P values) for all three genes re-
mained significant: SNP4 (RGS5) in AA samples, SNP26
(ATP1B1) in EA samples, and haplotype of SNP41–SNP43
(SELE) in AA samples.
To further validate the association signal in these three
genes, we replicated our findings in independently col-
lected samples from two other FBPP Networks, GENOA
and HyperGEN (the total number of samples studied was
4,079) (table 1). Nine SNPs in ATP1B1, RGS5, and SELE,
associated either individually or as haplotypes with P !
, were genotyped and analyzed using FBAT. We de-.01
tected significant association with BP in all three genes in
at least one sample group (table 5). Overall, we detected
evidence of association for RGS5 in four sample groups
(GenNet EA and AA samples and HyperGEN EA and AA
samples), with the strongest signal from SNP7 (Pp .002
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Table 5. Associations between RGS5, ATP1B1, and SELE SNPs and BP Levels
in the Original (GenNet) and Replication (HyperGEN and GENOA) Samples
Gene
and SNP
GenNet HyperGEN GENOA
EA AA EA AA EA AA
SBP DBP SBP DBP SBP DBP SBP DBP SBP DBP SBP DBP
RGS5:
4 … … .001b … … … … … … … … …
5a … … .005 … … … .04 .02 .07 … … …
6 … … .02 … … … … … … … … …
7a … … .002 .08 .001b .001b .02 .05 … … … …
8 … … .01 … … … … … … … … …
9 … .08 .04 … … … … … … … … …
10a … … .01 … … … .04 .03 .07 … … …
14 .009 .02 … … … … … … … … … …
ATP1B1:
16 … … … .02 … … … … … … … …
17 … … … .06 … … … … … … … …
18a .003 .01 … … .06 .05 … … … .02 … …
19 … .06 … .09 … … … … … … … …
20 … .06 … … … … … … … … … …
21 … .05 … … … … … … … … … …
23 … … .06 .04 … … … … … … … …
24a … .01 .007 .02 … … … … … … … .03
26a .0006b .03 … … … … … … … … … …
27a .004 .03 … … … … … … … … … …
28 … .03 … … … … … … … … … …
29 .02 .008 … … … … … … … … … …
SELE:
42a … … .07 … … … … … … … .01b .002b
43a … … .04 … … … … … … … … …
NOTE—Only SNPs with at least one FBAT P value ! .10 are shown. Cells with an ellipsis (…) are those
with FBAT P values ! .10 and those not genotyped in the replication samples. SBP and DBP were age and
sex adjusted. Medicated individuals were removed before analysis of GenNet samples, and their data were
adjusted on the basis of average treatment effect for analysis of HyperGEN and GENOA samples.
a SNPs genotyped in the replication samples.
b Associations that remain significant ( ) after Bonferroni correction for the number of indepen-P ! .05
dent SNPs tested.
and .001, for GenNet AA samples and HyperGEN EA sam-
ples, respectively). For ATP1B1, significant associations
were detected in four sample groups (GenNet EA and AA
samples and GENOA EA and AA samples), with the stron-
gest signal from SNP26 ( , for GenNet EA sam-Pp .0006
ples). For SELE, we detected association in two sample
groups, GenNet AA and GENOA AA samples, with the
strongest signal from SNP42 ( , for GENOA AAPp .002
samples). In these replication samples, association be-
tween SNP markers and SBP and DBP was significant for
both phenotypes (lower P values were observed for DBP;
data not shown). Importantly, for all SNPs that were sig-
nificantly associated with BP levels in multiple samples,
the associations were in the same direction (for example,
for SNP24 in GenNet AA and EA samples [fig. 2A] and
SNP42 in GenNet EA and GENOA AA samples [table 6]).
Replicated association signals are population specific;
what was significant for GenNet AA samples tended to be
significant for the AA samples of the replication samples
(for SNP5, SNP7, SNP10, SNP18, SNP24, and SNP42) (table
5). Furthermore, the association signals seen in RGS5 and
SELE (SNP7 and SNP42) were significant even after cor-
rection for multiple testing.
Phenotypic Effect Sizes of Hypertension-Susceptibility Alleles
Locus-specific phenotypic effects estimated from the same
population in which linkage was originally found are
sometimes inflated.35 Therefore, we estimated the phe-
notypic effect of RGS5, ATP1B1, and SELE, using not only
samples from GenNet but also samples from GENOA and
HyperGEN. We found significant and quantitatively sim-
ilar effect sizes for all three genes in the GenNet and
GENOA samples, with age- and sex-adjusted SBP effects
ranging from 1.5 to 5.1 mm Hg at individual SNPs (table
6). The HyperGEN samples, because of their smaller size,
have relatively less power to estimate the phenotypic ef-
fect size. Nevertheless, analysis of GENOA and HyperGEN
samples together yielded the same effect sizes for SNP5,
SNP10, and SNP42 as did analysis of GENOA samples
alone (data not shown). Furthermore, whenever the phe-
notypic effects of multiple genes were significant in the
same populations, we observed incremental increases in
mean BP in those samples, with more alleles associated
with higher BP (susceptibility alleles). For example, when
GenNet EA samples were grouped by their ATP1B1 and
SELE genotypes, their mean age- and sex-adjusted SBP in-
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Table 6. Phenotypic Effect Sizes
of SNPs Associated with BP
Gene
and SNP
Effect
(mm Hg) P Samples
RGS5:
5 1.7 .04 GENOA AA
6 1.8 .09 GenNet AA
7 2.2 .03 GenNet AA
8 2.1 .04 GenNet AA
9 3.6 .06 GenNet AA
10 1.5 .08 GENOA AA
ATP1B1:
23 4.3 .0005 GenNet EA
23 5.1 .04 GenNet AA
26 3.9 .001 GenNet EA
27 3.5 .005 GenNet EA
SELE:
42 2.7 .04 GenNet EA
42 2.3 .006 GENOA AA
43 1.8 .008 GenNet EA
44 1.7 .04 GenNet EA
NOTE.—The estimated phenotypic effects
are age- and sex-adjusted SBP in mm Hg.
Effect sizes with P values !.10 are listed. For
GenNet samples, only SBP values of unme-
dicated individuals were used for analysis.
For GENOA samples, SBP values adjusted for
medication effect were used in the analysis.
Figure 4. Cumulative phenotypic effects of ATP1B1, RGS5, and
SELE alleles. The effects of ATP1B1 and SELE alleles are both sig-
nificant in GenNet EA samples (for SNP26 and SNP43). The mean
adjusted SBP in those with zero, one, two, and three alleles as-
sociated with higher BP increased from 3.2 to 7.0 mm Hg in-
crementally with every additional susceptibility allele. The numbers
of GenNet EA individuals with zero, one, two, and three copies of
susceptibility alleles are 95, 352, 275, and 41, respectively. For
RGS5 and SELE alleles in GENOA AA samples (for SNP5 and SNP42),
the mean SBP increased from 6.3 to 1.3 mm Hg incrementally
with every additional susceptibility allele. The number of GENOA
AA individuals with one, two, three, and four copies of suscep-
tibility alleles are 52, 470, 673, and 266, respectively. In both
cases, the best-fitting line and the P values from Student’s t test
between those with the fewest and those with the most suscep-
tibility alleles are also shown.
creased from 3.2 to 7.0 mm Hg with each additional
susceptibility allele. This observation indicates that the
effects of multiple genes on BP are cumulative (fig. 4). The
combined effects on SBP are 10.2 and 7.8 mm Hg for
ATP1B1SELE and RGS5SELE, respectively.
In analyzing multiple study populations, some of which
were ascertained for BP values and some for hypertension
status, we encountered the problem of estimating true BP
levels from medicated individuals. The effect of treatment
was studied by using hypertension status instead of BP
values, by removing samples whose BP values are altered
by medication, by including them with the use of treated
BP values, or by including them with the use of BP values
adjusted by an estimated average treatment effect.12 We
found that, although P values varied, the overall pattern
of association remained the same (data available on re-
quest). Because the percentage of medicated subjects in
GenNet is relatively small (22%), removal of medicated
individuals from the analysis resulted in the most signif-
icant P values (fig. 2 and table 5). In contrast, 63% and
36% of GENOA and HyperGEN subjects, respectively, were
taking hypertension medication. In this situation, exclu-
sion of medicated individuals led to significant reductions
in power, and the most significant associations were de-
tected using BP values adjusted for average medication
effect.
Evidence That the Three Genes Are Independently Associated
with BP
The three associated genes are physically distant from
each other (RGS5–5.96 Mb–ATP1B1–616 kb–SELE). Im-
portantly, there is no evidence of LD or association be-
tween SNPS in these three genes. (Pairwise D’ values are
shown in fig. 3. All pairwise values of r2 for SNPs located
in different genes were !0.02.) In addition, conditional
association tests that analyzed only samples with the same
genotype in one gene (for example, SNP4 of RGS5 in
GenNet AA samples) still demonstrated significant asso-
ciation in the other two genes (data not shown).
Discussion
This study establishes that there are multiple BP-deter-
mining genes in the 1q linkage region. Importantly, it is
likely that most susceptibility alleles of complex diseases
have, individually, modest effects similar to those of the
RGS5, ATP1B1, and SELE alleles we studied. Hence, the
linkage signals uncovered by most genomewide linkage
studies likely arise from multiple genes in the same region
that have a combined phenotypic effect detectable by the
study sample size. In fact, the combined phenotypic ef-
fects of RGS5, ATP1B1, and SELE account for only a frac-
tion of the BP variants attributed to the 1q linkage region
(data not shown), and there are other, unidentified BP-
regulating genes in 1q. We hypothesize that clustering of
multiple genes that affect the same phenotype might be,
in some cases, evolutionarily advantageous. If so, such
regions can be identified by comparison of linkage signals
from multiple species, as we have done for BP-related loci
from human, mouse, and rat hypertension studies.
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The combined phenotypic effect of these 1q genes, es-
timated to be 8–10 mm Hg for SBP, is comparable to some
rare monogenic forms of hyper- and hypotension.36,37 For
example, the mitochondrial tRNA mutation that causes
hypomagnesemia, hypertension, and hypercholesterole-
mia (MIM 500005) has been found in a single family and
is associated with an age- and sex-adjusted SBP difference
of 13 mm Hg.36,37 In contrast, hypertension-susceptibility
alleles in RGS5, ATP1B1, and SELE are relatively common
(minor-allele frequencies range from 0.08 to 0.51) (table
4). Moreover, the combined phenotypic effect is similar
to several mouse models of hypertension, in which genes
central to BP regulation, such as AGT (MIM 106150),38
NPR1 (MIM 108960),39 NPPA (MIM 108780),40 NPR2 (MIM
108961),41 and AGTR1 (MIM 106165)42,43 have been de-
leted or duplicated. In these models, average BP difference
per copy ranges from 5 to 12 mm Hg. Furthermore, the
magnitude of the observed effect is similar to the average
effect of current hypertension treatment regimens on SBP
(a single medication at standard dosage).44 Consequently,
by physiological criteria, we have identified a locus with
major effects and common variants.
How are these three genes related to BP regulation?
ATP1B1 encodes the ubiquitously expressed b subunit of
Na,K-ATPase, an intrinsic oligomeric protein necessary for
the maintenance of Na and K electrochemical gradients
across the plasma membrane. This transporter is involved
in multiple BP-regulating physiological processes: renal so-
dium reabsorption, vascular smooth-muscle-tone regula-
tion, and cardiac muscle contraction. Decreased Na,K-
ATPase activity precedes the development of hypertension
in animal models.45 Although the a subunit has the cat-
alytic activity of the enzyme, the b subunit is required for
the proper cellular location of the enzyme and its stability.
In many cells and tissues, b mRNA is less abundant than
a mRNA, suggesting that the translation of b mRNA is a
crucial regulatory step in determining the abundance and
activity of this important enzyme.46–49
Regulators of G-protein signaling (RGSs) are a family of
proteins that promote GTPase activity of G-protein–cou-
pled receptors. RGS5 has several potential roles in BP reg-
ulation. First, RGS5 inhibits G-protein signaling by inac-
tivating Ga(q) and Ga(i), which mediate vasoconstrictors
such as angiotensin II and endothelin-1.50,51 Second, RGS5
is down-regulated during morphogenesis of the develop-
ing vasculature, and its expression is elevated in tumor-
associated blood vessels, suggesting a role in angiogen-
esis.52,53 Third, RGS5 might play a role in the sensing of
hemodynamic change and the remodeling of arteries.54 In
addition, RGS5 is down-regulated in stroke-prone spon-
taneously hypertensive rats, compared with in stroke-
resistant hypertensive rats, and is implicated in the path-
ogenesis of stroke.55
SELE encodes E-selectin, an endothelium-specific ad-
hesion molecule and a marker of endothelial function.
Endothelial dysfunction, or impaired endothelium-depen-
dent vasodilation, and elevated plasma levels of soluble
E-selectin are both common features of EH.56,57 Activated
endothelium promotes the formation of atheroma, re-
duces the elastic properties of the arterial wall, and alters
responsiveness to vasoactive stimuli. Endothelial dys-
function is likely a primary event in the development of
EH, and endothelial damage is exacerbated by the shear
stress of chronically elevated BP.58,59
Instead of a purely positional-cloning approach, we
opted to prioritize our association study by focusing on
genes with known or putative functions that are com-
patible with known BP-regulation physiology. The asso-
ciations between these three genes and BP levels have been
replicated in other samples. Analysis of all genes in the
1q linkage region can only confirm and will not diminish
our findings.
In ATP1B1, strong LD extends from SNP19 to SNP31, a
57.4-kb region that starts at intron 2 of ATP1B1 and ends
at the last two exons of an overlapping gene, NME7. Al-
though the SNPs located in ATP1B1 are more significantly
associated with BP levels than are SNPs in NME7, we have
not excluded NME7 from playing a role in BP regulation.
The same is true for the association observed between SELE
SNPs and BP; the associated SELE SNPs are in strong LD
with SNPs in SELL, a related gene that encodes lymphocyte
adhesion molecule 1, L-selectin.
We have not established which SNP in these three genes
are functionally responsible for BP-level differences. With
the exception of SNP42, a nonsynonymous coding SNP
in SELE, other SNPs significantly associated with BP levels
are located in either introns or UTRs. Some of these SNPs
are located in regions that are evolutionarily conserved.
For example, the most significantly associated SNP in our
study, SNP26, is located in the 3′ UTR of ATP1B1, a region
where human and distantly related species, such as tor-
pedo fish, share a high degree of sequence identity.60 We
suspect that the variants at this site or another site in LD
with SNP26 affect mRNA stability, translation efficiency,
or some other 3′-UTR–related function. Experiments to
confirm this hypothesis and to identify functional vari-
ants in RGS5 and SELE are underway.
So far, the identified genes underlying the rare and
monogenic forms of hypertension and hypotension are
all genes involved in renal sodium reabsorption. However,
the genes responsible for BP regulation and EH suscepti-
bility are not similarly limited in their functions, because
physiological studies have long established the impor-
tance of the vascular system in BP control and because
endothelial dysfunction and capillary rarefaction are both
hallmarks of EH.56,61 The findings of this study establish a
genetic association between BP regulation and genes in-
volved in vascular functions. Indeed, preliminary studies
indicated that genotypes of RGS5, ATP1B1, and SELE are
associated with varying levels of vascular responses to
stress (data not shown). Ultimately, knowledge of both
the genes that influence cardiac output through renal salt-
water balance and the genes that determine systemic re-
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sistance by modifying peripheral vasculature is important
for an understanding of EH.
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